Compounders Research Compare

CervoMed Inc.(CRVO)

Biotechnology · Boston, MA

$3.19-0.12 (-3.56%)

Delayed quote: Oct 6, 2026, 9:40 AM EDT

About CervoMed Inc.

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Boston, MA

15 employees

www.cervomed.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: John J. Alam

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T13:41:55.382Z.

Stored calculation inputs

Calculation as of: 2026-10-06T13:41:55.382Z.

Quote observation: 2026-10-06T13:40:05.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 29,553,831
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 22,462,577
TTM free cash flow · period ending 2026-06-30: -27,977,672

FMP input reference: 07daf27a5d98c2e6040b1a84eec716383e035dd1d7ed5c9da608703ba97b77ea

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CRVO EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

CRVO Competitors' EV/FCF Ratio

CervoMed Inc.

Current

Market Cap

$29.55M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

aTyr Pharma, Inc.

Market Cap

$28.87M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Baird Medical Investment Holdings Limited

Market Cap

$30.81M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Context Therapeutics Inc.

Market Cap

$31.22M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GridAI Technologies Corp.

Market Cap

$27.88M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

EUDA Health Holdings Limited

Market Cap

$31.30M

EV/FCF Ratio

N/A

TTM Avg

509.31x

3Y Avg

509.31x

5Y Avg

509.31x

BeyondSpring Inc.

Market Cap

$32.32M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HeartBeam, Inc.

Market Cap

$33.20M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Aligos Therapeutics, Inc.

Market Cap

$33.29M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ABVC BioPharma, Inc.

Market Cap

$25.48M

EV/FCF Ratio

N/A

TTM Avg

248.89x

3Y Avg

248.89x

5Y Avg

248.89x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
CervoMed Inc. (CRVO)	$29.55M	N/A	N/A	N/A	N/A
aTyr Pharma, Inc. (ATYR)vs ›	$28.87M	N/A	N/A	N/A	N/A
Baird Medical Investment Holdings Limited (BDMD)vs ›	$30.81M	N/A	N/A	N/A	N/A
Context Therapeutics Inc. (CNTX)vs ›	$31.22M	N/A	N/A	N/A	N/A
GridAI Technologies Corp. (GRDX)vs ›	$27.88M	N/A	N/A	N/A	N/A
EUDA Health Holdings Limited (EUDA)vs ›	$31.30M	N/A	509.31x	509.31x	509.31x
BeyondSpring Inc. (BYSI)vs ›	$32.32M	N/A	N/A	N/A	N/A
HeartBeam, Inc. (BEAT)vs ›	$33.20M	N/A	N/A	N/A	N/A
Aligos Therapeutics, Inc. (ALGS)vs ›	$33.29M	N/A	N/A	N/A	N/A
ABVC BioPharma, Inc. (ABVC)vs ›	$25.48M	N/A	248.89x	248.89x	248.89x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics